Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies

Annals of the Rheumatic Diseases

Volumn 77, Issue 4, 2018, Pages 549-555

  Kim, Mimi Y ^a   Guerra, Marta M ^b   Kaplowitz, Elianna ^b   Laskin, Carl A ^c   Petri, Michelle ^d   Branch, D Ware ^e   Lockshin, Michael D ^b,f   Sammaritano, Lisa R ^b,f   Merrill, Joan T ^g   Porter, T Flint ^e   Sawitzke, Allen ^e   Lynch, Anne M ^h   Buyon, Jill P ⁱ   Salmon, Jane E ^b,f  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF OKLAHOMA   (United States)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁱ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antiphospholipid syndrome; complement; inflammation; pregnancy; systemic lupus erythematosus

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT MEMBRANE ATTACK COMPLEX; PHOSPHOLIPID ANTIBODY; SC5B-9 PROTEIN COMPLEX;

ADVERSE OUTCOME; ARTICLE; BLOOD SAMPLING; CHROMOSOME ABERRATION; COMPLEMENT ACTIVATION; CONGENITAL INFECTION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FETUS DEATH; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; NEWBORN DEATH; PLACENTA INSUFFICIENCY; PREECLAMPSIA; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; ADULT; CASE CONTROL STUDY; CLINICAL TRIAL; FEMALE; IMMUNOLOGY; MULTICENTER STUDY; PREGNANCY; PREGNANCY COMPLICATION;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; CASE-CONTROL STUDIES; COMPLEMENT ACTIVATION; COMPLEMENT FACTOR B; COMPLEMENT MEMBRANE ATTACK COMPLEX; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME;

EID: 85044838883     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-212224     Document Type: Article

References (40)

1. Buyon JP, Kim MY, Guerra MM, et al. Predictors of pregnancy outcomes in patients with lupus: A cohort study. Ann Intern Med 2015;163:153-63.
2. Kim MY, Buyon JP, Guerra MM, et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol 2016;214:108. e1-14.
3. Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003;112:1644-54.
4. Qing X, Redecha PB, Burmeister MA, et al. Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int 2011;79:331-9.
5. Wang W, Irani RA, Zhang Y, et al. Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia. Hypertension 2012;60:712-21.
6. Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005;174:485-90.
7. Gelber SE, Brent E, Redecha P, et al. Prevention of defective placentation and pregnancy loss by blocking innate immune pathways in a syngeneic model of placental insufficiency. J Immunol 2015;195:1129-38.
8. Holers VM, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002;195:211-20.
9. Salmon JE, Heuser C, Triebwasser M, et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med 2011;8:e1001013.
10. R eggia R, Ziglioli T, Andreoli L, et al. Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications? Rheumatology 2012;51:2186-90.
11. D e Carolis S, Botta A, Santucci S, et al. Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome. Lupus 2012;21:776-8.
12. Buurma A, Cohen D, Veraar K, et al. Preeclampsia is characterized by placental complement dysregulation. Hypertension 2012;60:1332-7.
13. P enning M, Chua JS, van Kooten C, et al. Classical complement pathway activation in the kidneys of women with preeclampsia. Hypertension 2015;66:117-25.
14. Shamonki JM, Salmon JE, Hyjek E, et al. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007;196:167. e1-167. e5.
15. Cohen D, Buurma A, Goemaere NN, et al. Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss. J Pathol 2011;225:502-11.
16. Viall CA, Chamley LW. Histopathology in the placentae of women with antiphospholipid antibodies: A systematic review of the literature. Autoimmun Rev 2015;14:446-71.
17. O ku K, Atsumi T, Bohgaki M, et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009;68:1030-5.
18. Ziglioli T, Andreoli L MM. Low complement levels during pregnancy are associated with obstetric complications in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009;68:213-4.
19. Lynch AM, Salmon JE. Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. Placenta 2010;31:561-7.
20. Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
21. Lockshin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012;64:2311-8.
22. Girardi G, Yarilin D, Thurman JM, et al. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006;203:2165-75.
23. T hurman JM, Kraus DM, Girardi G, et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol 2005;42:87-97.
24. Lynch AM, Wagner BD, Giclas PC, et al. The relationship of longitudinal levels of complement Bb during pregnancy with preeclampsia. Am J Reprod Immunol 2016;75:104-11.
25. Banadakoppa M, Vidaeff AC, Yallampalli U, et al. Complement split products in amniotic fluid in pregnancies subsequently developing early-onset preeclampsia. Dis Markers 2015;2015:1-7.
26. Hoffman MC, Rumer KK, Kramer A, et al. Maternal and fetal alternative complement pathway activation in early severe preeclampsia. Am J Reprod Immunol 2014;71:55-60.
27. Lynch AM, Murphy JR, Gibbs RS, et al. The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG 2010;117:456-62.
28. Burwick RM, Fichorova RN, Dawood HY, et al. Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension 2013;62:1040-5.
29. Guseh SH, Feinberg BB, Dawood HY, et al. Urinary excretion of C5b-9 is associated with the anti-angiogenic state in severe preeclampsia. Am J Reprod Immunol 2015;73:437-44.
30. Sammaritano LR, Ng S, Sobel R, et al. Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis. Arthritis Rheum 1997;40:1998-2006.
31. Kolev M, Le Friec G, Kemper C. Complement-tapping into new sites and effector systems. Nat Rev Immunol 2014;14:811-20.
32. Wells M, Bennett J, Bulmer JN, et al. Complement component deposition in uteroplacental (spiral) arteries in normal human pregnancy. J Reprod Immunol 1987;12:125-35.
33. Morgan BP, Holmes CH. Immunology of reproduction: protecting the placenta. Curr Biol 2000;10:R381-R383.
34. T edesco F, Narchi G, Radillo O, et al. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. J Immunol 1993;151:1562-70.
35. Holmes CH, Simpson KL, Wainwright SD, et al. Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy. J Immunol 1990;144:3099-105.
36. Cunningham DS, Tichenor JR. Decay-accelerating factor protects human trophoblast from complement-mediated attack. Clin Immunol Immunopathol 1995;74:156-61.
37. P utterman C, Furie R, Ramsey-Goldman R, et al. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Sci Med 2014;1:e000056.
38. Breen KA, Seed P, Parmar K, et al. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb Haemost 2012;107:423-9.
39. Buyon JP, Tamerius J, Ordorica S, et al. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum 1992;35:55-61.
40. Abramson SB, Buyon JP. Activation of the complement pathway: comparison of normal pregnancy, preeclampsia, and systemic lupus erythematosus during pregnancy. Am J Reprod Immunol 1992;28:183-7.